Pancreatic cancer cells lacking the MTAP gene rely on specific alternative metabolic pathways for survival, and these pathways can be blocked by drugs to kill the cancer cells.
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
Pancreatic cancer cells lacking the MTAP gene rely on specific alternative metabolic pathways for survival, and these pathways can be blocked by drugs to kill the cancer cells.
See the technical phrasing
Loss of the MTAP gene in pancreatic cancer establishes a synthetic lethal dependency on alternative metabolic pathways that can be pharmacologically inhibited.
When the MTAP gene is lost, cancer cells can't recycle a key molecule called MTA, which builds up and blocks a protein needed for proper RNA splicing. This causes errors in how essential genes are read, especially those involved in DNA repair and cell division. At the same time, the cell becomes dependent on a backup enzyme to make a critical molecule for both splicing and DNA building blocks. Blocking that backup enzyme starves the cell of both functions at once, causing catastrophic DNA damage during replication and killing only the cancer cells.
What the research says
Supports
3 studies
Study: Therapeutic vulnerabilities exposed by the 9p21 loss identified through multiparametric drug screening inform rational combination strategies.
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 3 supporting studies